Eli Lilly’s Emgality is Perceived as Increasingly Competitive with Amgen/Novartis’ Aimovig and Teva’s Ajovy in the US Migraine Prevention Market, as the Anti-CGRP Brand Pulls Ahead on Payer Approval Ease and Overall Prescriber Satisfaction
Assuming positive regulatory outcomes for the preventive treatment of migraine, Biohaven Pharmaceuticals’ rimegepant and Allergan’s atogepant will quickly erode injectable anti-CGRP therapy share, resulting in a dominant position within the class, according to the 4th wave of Spherix Global Insights’ report series Download Report Overview EXTON, Pa., July 2, 2019 ― US neurologists and migraine […]
Biogen Drops After Piper Jaffray Downgrade, Price Target Cut
From: TheStreet By: Tony Owusu Biogen shares were falling in trading Friday after analysts at Piper Jaffray downgraded the stock to neutral from overweight on concerns about competitive pressures for the suite of the company’s multiple sclerosis treatments. The firm also lowered its price target to $250 from […]
Biogen Stock Is Slipping Because a Multiple Sclerosis Drug Has Fierce Competition
From: Barron’s By: Josh Nathan-Kazis Biogen stock was slipping on Friday morning as one analyst warned that the company’s drug for multiple sclerosis could be losing ground to new competitors. Citing data from a proprietary survey of doctors treating MS patients, PiperJaffray analyst Christopher Raymond outlined threats to […]
With Novartis’ Mayzent Firmly Positioned for Transitioning Relapsing-Remitting Multiple Sclerosis and Secondary Progressive Multiple Sclerosis Use, EMD Serono’s Mavenclad Could Be Most Competitive as an Ideal First Switch Following Efficacy Failure
Bolstering Tecfidera’s competitiveness with the glatiramer acetate class among treatment-naïve relapsing-remitting multiple sclerosis patients is Biogen’s best defense against anticipated near-term share constriction, according to the 14th wave of the quarterly Spherix Global Insights report Download Report Overview EXTON, Pa., June 26, 2019 ― During the last week of March 2019, both Novartis’ Mayzent and […]
US Nephrologists Report Few Gains in the CKD-MBD Market for Akebia’s Auryxia, Amgen’s Parsabiv, and Opko’s Rayaldee Despite Reports That They Would Like to Expand Use of All Three Products
According to the latest quarterly update from Spherix Global Insights, strict protocols at large dialysis organizations (LDOs) are the leading barrier to increased use of Parsabiv while market access pressures remain the primary obstacle for Auryxia and Rayaldee. Download Report Overview JUNE 25, 2019, EXTON, PA – According to a survey of 202 nephrologists in […]
US Gastroenterologists Report VARSITY Trial Data and JAK Inhibitor Safety Concerns Will Impact Their Prescribing Behavior in Ulcerative Colitis, with Potential Implications for Crohn’s Treatment
Takeda’s Phase 3b head-to-head study comparing Entyvio to AbbVie’s Humira, as well as preliminary results of an ongoing post-marketing requirement study for Pfizer’s Xeljanz regarding safety are beginning to affect gastroenterologists’ perceptions and use of key brands for the treatment of inflammatory bowel disease. Download Report Overview EXTON, Pa., June 5, 2019 /PRNewswire/ — While both […]
EMD Serono’s Mavenclad Edges Past Novartis’ Gilenya in the Recent Switch Segment of Canada’s Multiple Sclerosis Market, Although Brand Familiarity Remains An Addressable Barrier
Even with the recent favorable conclusion to pan-Canadian Pharmaceutical Alliance negotiations, the prescriber base for Roche’s Ocrevus may be nearing a plateau requiring existing prescribers to fuel the majority of anticipated brand growth, according to the inaugural Canada report from Spherix Global Insights Download Report Overview EXTON, Pa., May 28, 2019 ― Therapeutic choice for […]
US Dermatologists Report a Sizeable Portion of Their Atopic Dermatitis Patients Currently Treated with Sanofi/Regeneron’s Dupixent Would be Switched to Another Targeted Therapy if Available
According to a recent study conducted by Spherix Global Insights, Dupixent continues to be well-received amongst US dermatologists, though overall use will likely take a hit once new advance systemic treatments become available. Download Report Overview EXTON, Pa., May 15, 2019 /PRNewswire/ —In Spherix’s second quarter update of RealTime Dynamix™: Atopic Dermatitis (US), Sanofi/Regeneron’s Dupixent […]
Biogen’s Tecfidera Share of the Multiple Sclerosis Switch Segment Continues a Three-Year Downward Trend to the Benefit of Novartis’ Gilenya and Genentech’s Ocrevus
EMD Serono and Novartis will have the greatest opportunity to drive patient switches to Mavenclad and Mayzent, respectively, within the first six months following transition to secondary progressive multiple sclerosis, according to a new audit by Spherix Global Insights Download Report Overview EXTON, Pa., April 29, 2019 ― According to Spherix’s new RealWorld Dynamix™: DMT […]
In Psoriasis, Use of the IL-17 Inhibitors, Novartis’ Cosentyx and Eli Lilly’s Taltz, are Neck and Neck, but the Former Still Holds a Significant First-to-Market Edge Amongst Rheumatologists for the Treatment of Psoriatic Arthritis, According to Data Recently Collected by Spherix Global Insights
After several years on the market, the majority of US dermatologists report that Cosentyx has lost its advantage over Taltz as the first IL-17 inhibitor on the market; with increased penetration of Taltz for the treatment of psoriatic arthritis, will rheumatologists follow suit? Download Report Overview EXTON, Pa., April 17, 2019 /PRNewswire/ — Spherix Global Insights […]
